Cellectis (CLLS)

• Market cap: $132M
• 1 day: 6.45%
• 5 days: -0.75%
• 1 month: 2.33%
• 3 months: -27.07%
• 6 months: -34.65%
• Year to date: -27.07%
• 1 year: -48.03%
• 5 years: -84.67%
• 10 years: -96.06%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $6K | Put options by funds: $3K

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

10% more capital invested

Capital invested by funds: $20.9M [Q3] → $23M (+$2.1M) [Q4]

7% more funds holding

Funds holding: 27 [Q3] → 29 (+2) [Q4]

4.15% more ownership

Funds ownership: 13.55% [Q3] → 17.7% (+4.15%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6